<DOC>
	<DOCNO>NCT02894944</DOCNO>
	<brief_summary>Pancreatic cancer associate extremely poor prognosis , reflect 5-y survival probability le 5 % stage combine . At present , approximately 10 % -20 % patient consider candidate curative resection . The majority patient ( 50 % -60 % ) present metastatic disease , substantial number patient ( approximately 30 % -40 % ) consider `` locally advanced '' time diagnosis . Replication-competent Adenovirus-mediated Double Suicide Gene Therapy ( Theragene® , Ad5-yCD/mutTKSR39rep-ADP ) show anti-cancer effect patient prostatic cancer phase I study . From experience prostatic cancer , safety combination standard chemotherapy Theragene treatment assess study .</brief_summary>
	<brief_title>Clinical Trial Phase I Theragene Combination With Chemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Patients pancreatic cancer stage 3 Patients histologically confirm pancreatic adenocarcinoma Patients evidence peritoneal hematogenous metastasis Patients ECOG performance status 02 Patients renal function ( Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 50 mL/min/m² ) Patients bone marrow function ( WBC &gt; 4,000/uL absolute neutrophil count ≥ 1500/uL , PLT ≥ 100,000/uL , Hemoglobin &gt; 10 g/dL ) Patients liver function ( Bilirubin &lt; 2.0 mg/dL SGOT SGPT &lt; 2.5 time upper limit normal ( ULN ) ) Patients agreement inform consent Male patient contraception Female patient childbearing age pregnancy breast feeding Patients history chemotherapy within 5 year Patients history radiation 25 % bone marrow Patients unknown stage recurrent pancreatic cancer Patients history skin cancer except malignant melanoma malignancy except stage 0 cervical cancer Patients history major surgery except laparoscopic exam , endoscopic ultrasound , stenting , PEG/PEJ placement Patients active uncontrolled infection Patients immunosuppression susceptibility viral infection Patients HIV infection , chronic hepatitis B , chronic hepatitis C , liver cirrhosis Patients history allergy clinical trial medication Patients consider inappropriate candidate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Adenovirus</keyword>
	<keyword>Gene therapy</keyword>
</DOC>